Risk factor
Very high price volatility
Profitability factor
Strong growth
About
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of CU6.AX is 6.7 and suggests 94% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell